Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 6/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10121668 | 0.91 | GHSR (0.55) | GHSRMCHR1NAMPTAURKAAURKB | |
| SCHEMBL1709689 | 0.90 | GHSR (0.57) | GHSRNAMPTAURKAAURKBPOLB | |
| SCHEMBL10121950 | 0.85 | GHSR (0.64) | GHSRAURKAAURKBEPHX2POLB | |
| SCHEMBL10121959 | 0.84 | GHSR (0.59) | GHSRNAMPTAURKAAURKB | |
| SCHEMBL17631733 | 0.84 | GHSR (0.82) | GHSRMCHR1 | |
| SCHEMBL10121682 | 0.84 | GHSR (0.69) | GHSRPPARAPPARG | |
| SCHEMBL10121689 | 0.83 | GHSR (0.61) | GHSREPHX2 | |
| SCHEMBL10122103 | 0.83 | GHSR (0.65) | GHSR | |
| SCHEMBL10122211 | 0.83 | GHSR (0.60) | GHSRPOLB | |
| SCHEMBL10121676 | 0.82 | GHSR (0.64) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | GHSR 1/4885MCHR1 378/4885NAMPT 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.